Innospec
Market Cap
US$2.4b
Last Updated
2019/11/20 00:03 UTC
Data Sources
Company Financials +
Executive Summary
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals worldwide.
Snowflake
Fundamentals
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Innospec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IOSP has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.8%
IOSP
-1.1%
US Chemicals
0.9%
US Market
1 Year Return
37.0%
IOSP
-1.9%
US Chemicals
16.8%
US Market
Return vs Industry: IOSP exceeded the US Chemicals industry which returned -1.9% over the past year.
Return vs Market: IOSP exceeded the US Market which returned 16.8% over the past year.
Shareholder returns
| IOSP | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.8% | -1.1% | 0.9% |
| 30 Day | 4.9% | 4.8% | 4.5% |
| 90 Day | 16.0% | 7.7% | 6.2% |
| 1 Year | 38.6%37.0% | 13.3%-1.9% | 19.4%16.8% |
| 3 Year | 50.8%45.6% | 40.0%14.0% | 47.5%38.0% |
| 5 Year | 135.3%121.6% | 42.6%10.7% | 62.0%44.1% |
Price Volatility Vs. Market
How volatile is Innospec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
This Insider Has Just Sold Shares In Innospec Inc. (NASDAQ:IOSP)1 week ago | Simply Wall St
There's A Lot To Like About Innospec Inc.'s (NASDAQ:IOSP) Upcoming 0.5% Dividend1 week ago | Simply Wall St
Results: Innospec Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesValuation
Is Innospec undervalued compared to its fair value and its price relative to the market?
23.46x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IOSP ($97.34) is trading above our estimate of fair value ($91.95)
Significantly Below Fair Value: IOSP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IOSP is poor value based on its PE Ratio (23.5x) compared to the Chemicals industry average (19.6x).
PE vs Market: IOSP is poor value based on its PE Ratio (23.5x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: IOSP is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: IOSP is overvalued based on its PB Ratio (2.7x) compared to the US Chemicals industry average (2.1x).
Next Steps
Future Growth
How is Innospec forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
12.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IOSP's forecast earnings growth (12.2% per year) is above the savings rate (2.7%).
Earnings vs Market: IOSP's earnings (12.2% per year) are forecast to grow slower than the US market (14.4% per year).
High Growth Earnings: IOSP's earnings are forecast to grow, but not significantly.
Revenue vs Market: IOSP's revenue (1.7% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: IOSP's revenue (1.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IOSP's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Innospec performed over the past 5 years?
-4.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IOSP has high quality earnings.
Growing Profit Margin: IOSP's current net profit margins (6.7%) are higher than last year (4.2%).
Past Earnings Growth Analysis
Earnings Trend: IOSP's earnings have declined by -4.9% per year over the past 5 years.
Accelerating Growth: IOSP's earnings growth over the past year (69.7%) exceeds its 5-year average (-4.9% per year).
Earnings vs Industry: IOSP earnings growth over the past year (69.7%) exceeded the Chemicals industry -20.1%.
Return on Equity
High ROE: IOSP's Return on Equity (11.5%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Innospec's financial position?
Financial Position Analysis
Short Term Liabilities: IOSP's short term assets ($673.3M) exceeds its short term liabilities ($296.7M)
Long Term Liabilities: IOSP's short term assets ($673.3M) exceeds its long term liabilities (315.5M)
Debt to Equity History and Analysis
Debt Level: IOSP's debt to equity ratio (14.9%) is considered satisfactory.
Reducing Debt: IOSP's debt to equity ratio has reduced from 25.2% to 14.9% over the past 5 years.
Debt Coverage: IOSP's debt is well covered by operating cash flow (131.9%).
Interest Coverage: IOSP's interest payments on its debt are well covered by EBIT (28.9x coverage).
Balance Sheet
Inventory Level: IOSP has a high level of physical assets or inventory.
Debt Coverage by Assets: IOSP's debt is covered by short term assets (assets are 5.1x debt).
Next Steps
Dividend
What is Innospec's current dividend yield, its reliability and sustainability?
1.07%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: IOSP's dividend (1.07%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.43%).
High Dividend: IOSP's dividend (1.07%) is low compared to the top 25% of dividend payers in the US market (3.68%).
Stability and Growth of Payments
Stable Dividend: IOSP's dividend payments have been volatile in the past 10 years.
Growing Dividend: IOSP's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.6%), IOSP's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of Innospec's salary, the management and board of directors tenure and is there insider trading?
7.3yrs
Average management tenure
CEO
Patrick Williams (54yo)
10.6yrs
Tenure
US$5,413,268
Compensation
Mr. Patrick S. Williams has been the Chief Executive Officer and President at Innospec Inc. since April 2, 2009. He has been a Director of Innospec Inc, since April 2, 2009. Mr. Williams has been the Chief ...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD5.41M) is above average for companies of similar size in the US market ($USD3.91M).
Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.
Management Age and Tenure
7.3yrs
Average Tenure
60yo
Average Age
Experienced Management: IOSP's management team is seasoned and experienced (7.3 years average tenure).
Board Age and Tenure
10.0yrs
Average Tenure
64yo
Average Age
Experienced Board: IOSP's board of directors are seasoned and experienced ( 10 years average tenure).
Insider Trading
Insider Buying: IOSP insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Operating Officer COO & Executive VP |
| Shares | 26,820 |
| Max Price | US$97.57 |
| Entity | Individual |
| Role | Head of Human Resources Senior Vice President of Human Resources |
| Shares | 5,000 |
| Max Price | US$99.59 |
| Entity | Individual |
| Role | Chief Financial Officer Executive VP & CFO |
| Shares | 2,000 |
| Max Price | US$99.40 |
| Entity | Individual |
| Role | Head of Investor Relations Senior Vice President of Corporate Development & Investor Relations |
| Shares | 3,000 |
| Max Price | US$84.16 |
| Entity | Individual |
| Shares | 300 |
| Max Price | US$83.12 |
| Entity | Individual |
| Role | Head of Human Resources Senior Vice President of Human Resources |
| Shares | 2,000 |
| Max Price | US$83.97 |
| Entity | Individual |
| Role | Head of Investor Relations Senior Vice President of Corporate Development & Investor Relations |
| Shares | 2,000 |
| Max Price | US$82.54 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 400 |
| Max Price | US$81.51 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 14,062 |
| Max Price | US$83.57 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 7,030 |
| Max Price | US$84.94 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 13,508 |
| Max Price | US$84.62 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Steve Williams (63yo)
Executive Director
- Tenure: 0yrs
Philip Boon (60yo)
COO & Executive VP
- Tenure: 4yrs
- Compensation: US$1.28m
Ian McRobbie (70yo)
Chief Technology Officer and Senior VP of Research & Technology
- Tenure: 17.5yrs
- Compensation: US$869.22k
Cathy Hessner (60yo)
Senior Vice President of Human Resources
- Tenure: 16.3yrs
- Compensation: US$649.28k
Patrick Williams (54yo)
President
- Tenure: 10.6yrs
- Compensation: US$5.41m
Ian Cleminson (53yo)
Executive VP & CFO
- Tenure: 13.3yrs
- Compensation: US$1.20m
Brian Watt (60yo)
Senior Vice President of Corporate Development & Investor Relations
- Tenure: 2.3yrs
- Compensation: US$945.95k
Tom Entwistle
President of Oilfield Services - Americas
- Tenure: 0yrs
Christopher Parsons (42yo)
Head of Group Finance
- Tenure: 2.9yrs
David Jones (50yo)
VP, General Counsel
- Tenure: 1.7yrs
Board Members
Claudia Poccia (59yo)
Non-Executive Director
- Tenure: 0.3yrs
David Landless (60yo)
Non-Employee Director
- Tenure: 3.8yrs
- Compensation: US$138.18k
Hugh Graham Aldous (74yo)
Non-Executive Director
- Tenure: 14.8yrs
- Compensation: US$135.18k
Patrick Williams (54yo)
President
- Tenure: 10.6yrs
- Compensation: US$5.41m
Joachim Roeser (65yo)
Non-Executive Director
- Tenure: 11.8yrs
- Compensation: US$137.18k
Bob Paller (85yo)
Non-Executive Director
- Tenure: 10yrs
- Compensation: US$137.18k
Larry Padfield (63yo)
Non-Executive Director
- Tenure: 6.9yrs
- Compensation: US$122.90k
Bud Blackmore (71yo)
Non-Executive Chairman
- Tenure: 0yrs
- Compensation: US$207.18k
Company Information
Innospec Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Innospec Inc.
- Ticker: IOSP
- Exchange: NasdaqGS
- Founded: 1938
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: US$2.384b
- Shares outstanding: 24.50m
- Website: https://www.innospecinc.com
Number of Employees
Location
- Innospec Inc.
- 8310 South Valley Highway
- Suite 350
- Englewood
- Colorado
- 80112
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IOSP | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 1998 |
| OCT | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1998 |
| 0JAX | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1998 |
Biography
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/20 00:03 |
| End of Day Share Price | 2019/11/19 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.